This drug can fight more than 300 drug-resistant bacteria

A team of researchers has developed a new drug molecule that could help overcome more than 300 drug-resistant bacteria.

The drug compound, called fabimycin, reported in the ACS Central Science journal, inhibited drug-resistant Gram-negative bacteria in laboratory experiments, as well as pneumonia and urinary tract infections in rats.

Gram-negative bacteria are a class of microbes that infect millions of people worldwide, and are particularly difficult to treat because they have strong defense systems – tough cell walls that keep most antibiotics out and Pumps that efficiently remove the antibiotics that get in.

Germs can also mutate to survive many drugs. In addition, the treatments that work are not very specific, eliminating many types of bacteria, including beneficial ones.

Fabimycin, developed by a team from the University of Illinois in the US, showed the ability to infiltrate the defenses of Gram-negative bacteria and treat infections, while leaving other helpful microbes intact.

The team, led by Paul Hergenröder of the university’s Department of Chemistry, started with an antibiotic that was active against Gram-positive bacteria and made a series of structural modifications that they believed were effective against Gram-negative strains. will be allowed to act against.

Fabimycin proved to be potent against more than 300 drug-resistant clinical isolates, while remaining relatively inactive against some Gram-positive pathogens and some generally harmless bacteria that live in or on the human body.

In addition, the new molecule reduced the amount of drug-resistant bacteria in mice with pneumonia or urinary tract infections at or below the level before infection, as well as outperforming existing antibiotics at similar doses.

Researchers said the results suggest that fabimycin may one day be an effective treatment for stubborn infections.

Subscribe

Get the best of Newspaper delivered to your inbox daily

Most Viewed

Related Stories